FYI ---------- Forwarded message --------- From: Joseph Wu <joewu@stanford.edu> Date: Tue, Feb 15, 2022 at 9:39 PM Subject: RE: in silico modeling expert To: Brian Shoichet <bshoichet@gmail.com> Dear Brian, I hope all is well. I recently started a startup company using clinical genomics, AI/ML, and patient-specific iPSCs to accelerate drug discovery. I wonder if you know of any graduates in your program or department who may be interested in joining our company. The expertise would be as follow: 1.) Computational ligand screening (e.g. docking) for hit identification 2.) Hit-to-lead optimization for establishing quantitative structure-activity-relationship (QSAR) 3.) Computational protein modeling, e.g. homology modeling. If yes, please feel free to introduce me to him/her and I’ll be happy to set up a zoom call. Thank you in advance. Best wishes, Joe Joseph C. Wu, MD, PhD Director, Stanford Cardiovascular Institute Simon H. Stertzer, MD, Professor of Medicine & Radiology Stanford University School of Medicine 265 Campus Drive, Rm G1120B Stanford, CA 94305-5454 Ph: 650-736-2246; Fax: 650-736-0234 Email: joewu@stanford.edu Lab: http://wulab.stanford.edu Stanford CVI: http://med.stanford.edu/cvi <http://med.stanford.edu/cvi.html> [image: cid:image001.jpg@01D58538.54058B90] <http://med.stanford.edu/cvi.html> [image: cid:ff7027d6-b10c-47d4-9a0c-6aac03848d78] <https://twitter.com/Joseph_C_Wu> *From:* Brian Shoichet <bshoichet@gmail.com> *Sent:* Wednesday, November 3, 2021 11:19 AM *To:* Hao Zhang <zhanghao@stanford.edu> *Cc:* Stefan Gahbauer <steffgahbauer@gmail.com>; Joseph Wu < joewu@stanford.edu> *Subject:* Re: Mentor team for my career development grant (in collaboration with Stefan) Hi Hao, Yes, I'd be willing to do it. Brian On Wed, Nov 3, 2021 at 8:06 AM Hao Zhang <zhanghao@stanford.edu> wrote: Dear Brian, I hope you are doing well. In the past few months, Stefan and I have been working together to design novel compounds aiming to eliminate neurological off-target effects in CGS15943, a non-selective adenosine antagonist for antifibrotic therapy. Stefan and I had many discussions, in which he taught me the strategy for in-silico drug development, including ligand-receptor docking, protein homology prediction, and polarized side-chain design. The new design compound is being synthesized, and we will test the effects soon. I am writing a career development grant for the American Heart Association. As "in-silico based drug development" takes a major part of my proposal. I wonder if you would like to join my mentor team, responsible for the drug design. Our chemistry department or CRO is responsible for the chemical synthesis with your supervision. I can draft the mentor letter with your approval. Thanks for your consideration. Best wishes, Hao -- Brian Shoichet, Professor, UCSF latest science from the lab: *http://www.bkslab.org/ <http://www.bkslab.org/contact.php>* -- Brian Shoichet, Professor, UCSF latest science from the lab: *https://bkslab.org/ <https://bkslab.org/>*